|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, October 08, 2018 ) The Global Antiplatelet Drugs Market, by Drug Class (Irreversible Cyclooxygenase (COX) Inhibitors, Adenosine Diphosphate (ADP) Receptor Inhibitors, Glycoprotein IIB/IIIA Inhibitors, Adenosine Reuptake Inhibitors, and Thromboxane Inhibitors and Phosphodiesterase Inhibitors), by Mode of Administration (Oral and Intravenous), by Application (Angioplasty, Arterial Thrombosis, Myocardial Infarction, Percutaneous Coronary Interventions, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 1.5 billion in 2017 and is projected to exhibit a CAGR of 7.6% over the forecast period (2018 - 2026), as highlighted in a new report published by Coherent Market Insights.
Request Sample Copy of the Report @ https://www.coherentmarketinsights.com/insight/request-sample/2190
Antiplatelet therapy is considered to be crucial in preventing aberrant platelet activation in pathophysiological conditions such as ischemia, myocardial infarction, and stroke. According to the Indian Journal of Pharm Science 2007 study, antiplatelet drugs reduce the incidence of cardiovascular events by 20-25% in people with established Coronary Artery Disease (CAD) or at high risk of CAD.
Manufactures in the antiplatelet drugs market focus on targeting either surface receptors or enzymes in the platelet in order to protect against unwanted clot formation following initial platelet activation. Sustained development of new antiplatelet therapies is required as the risk for myocardial infarction and stroke, and death remain a persistent problem for individuals suffering from cardiovascular diseases.
Browse 31 Market Data Tables and 33 Figures spread through 185 Pages and in-depth TOC on "Global Antiplatelet Drugs Market, by Drug Class (Irreversible Cyclooxygenase (COX) Inhibitors, Adenosine Diphosphate (ADP) Receptor Inhibitors, Glycoprotein IIB/IIIA Inhibitors, Adenosine Reuptake Inhibitors, and Thromboxane Inhibitors and Phosphodiesterase Inhibitors), by Mode of Administration (Oral and Intravenous), by Application (Angioplasty, Arterial Thrombosis, Myocardial Infarction, Percutaneous Coronary Interventions, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2026"
To know the latest trends and insights related to antiplatelet drugs market, click the link below:
https://www.coherentmarketinsights.com/market-insight/antiplatelet-drugs-market-2190
Moreover, cost of drugs is also an important factor influencing compliance with treatment of disease and also constitutes an essential part of rational drug prescription. Pharmaceutical industry has several branded formulation of the same drug with large difference in selling price. For instance, in India, most of the drugs are available in brands and these drugs prescribed by clinician can adversely affect the patient’s finance.
According to a study published in The International Journal of Basic & Clinical Pharmacology, 2016, the difference in the maximum and minimum price of the same drug manufactured by various pharmaceutical companies and percentage variation in cost per 10 tablets was calculated. Percentage variation in cost for oral antiplatelet drugs marketed in India was found to be- clopidogrel 150 mg tablet (148.7%), clopidogrel 75 mg (1067.3%), clopidogrel 300 mg tablet (42.9%), aspirin 75 mg (51.5%), aspirin 150 mg (69.8%), prasugrel 5 mg (94.4%), prasugrel 10 mg (54.8%), and ticlopidine 250 mg (32%). The lowest percent cost variation found is— ticagrelor 90 mg (0%).
In combination therapy the highest price variation (235.6%) was found for aspirin (75 mg) and clopidogrel (75 mg) followed by aspirin (150 mg) and clopidogrel (75 mg) (24.2%). Therefore, there is a great need for the development of antiplatelet drug with low cost and less side effects along with great efficacy.
Ask for a Discount @ https://www.coherentmarketinsights.com/insight/request-discount/2190
Key Takeaways of the Antiplatelet Drugs Market:
The global antiplatelet drugs market is expected to witness a CAGR of 7.6% during the forecast period, owing to increasing prevalence of cardiovascular diseases. According to Centers for Disease Control and Prevention, in 2016, there were around 40,000 children born with coronary heart disease in the U.S.
Among mode of administration, the oral segment is expected to generate significant revenue in 2018, owing to increasing number of oral products available in market.
Major players operating in the global antiplatelet drugs market include, AstraZeneca Plc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo, Inc., Eli Lilly and Company, Merck & Co., Inc., Otsuka Pharmaceutical Company, Ltd., Sanofi, and The Medicines Company.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com
Coherent Market Insights
Mr. Shah
2067016702
sales@coherentmarketinsights.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
